1. Repositório Institucional - Universidade Federal de Uberlândia
2. Instituto de Ciências Biomédicas (ICBIM)
3. TCC - Ciências Biomédicas

ORCID:	http://orcid.org/0009-0001-6214-2632
Document type:	Trabalho de Conclusão de Curso
Access type:	Acesso Embargado
Embargo Date:	2027-06-25
Title:	Combatendo o vírus Zika com um complexo de cobalto(II) e uma base de Schiff derivada da amantadina: uma nova estratégia para o desenvolvimento de fármacos antivirais
Alternate title (s):	Targeting Zika virus with a cobalt(II) complex and a Schiff base derived from amantadine: a new strategy for antiviral drug development
Author:	d'Almeida, Júlia Amaral Vieira
First Advisor:	Jardim, Ana Carolina Gomes
First coorientator:	Cassani, Natasha Marques
First member of the Committee:	Calmon, Marillia de Freitas
Second member of the Committee:	Souza, Eliza Flores de
Summary:	Zika fever is a disease caused by the Orthoflavivirus zikaense (Zika virus, ZIKV), mainly transmitted by mosquitoes from the genus Aedes. It has been previously associated with cases of microcephaly and Guillain-Barré syndrome, drawing the attention of the health authorities worldwide. However, there are no vaccines and antivirals available against ZIKV, and therefore, the search for compounds with antiviral activity is mandatory. In this context, metallodrugs have demonstrated antiviral activity against several viruses. Here we demonstrated the anti-ZIKV activity of the cobalt ion (Co) coordinated to a Schiff base derived from amantadine using salicylaldehyde (atdSali), a complex named Co-atdSali, compared to the antiviral activity of its ligands. Vero E6 cells were infected with ZIKVPE243 in the presence of compounds at non-cytotoxic concentrations for 72 hours, when virus titers were evaluated, through immunofluorescence, and cytotoxicity, through MTT assay. Results demonstrated a strong anti-ZIKV activity, with Co-atdSali reducing over 91% of ZIKV infection, whereas Co(II) and atdSali reduced 44 and 8% of ZIKV replication, respectively. Moreover, the complex presented strong dose-response inhibition of ZIKV replication, with a SI of 14.7, when compared to its ligands, Co(II) and atdSali, that presented a SI of 3.9 and 1.6, respectively. Our findings show that the coordination of Co(II) to the atdSali ligand leads to a complex with enhanced antiviral activity when compared to the free ligands indicating its usage as a template for the development of future antiviral candidate drugs against Zika fever.
Keywords:	Antivirais Zika virus Complexo metálico Cobalto Antiviral drugs Metallic complex Cobalt
Area (s) of CNPq:	CNPQ::CIENCIAS DA SAUDE CNPQ::CIENCIAS BIOLOGICAS::MICROBIOLOGIA
Language:	eng
Country:	Brasil
Publisher:	Universidade Federal de Uberlândia
Quote:	D'ALMEIDA, Júlia A. V. Combatendo o vírus Zika com um complexo de cobalto(II) e uma base de Schiff derivada da amantadina: uma nova estratégia para o desenvolvimento de fármacos antivirais. 2025. 23 f. Trabalho de Conclusão de Curso (Graduação em Biomedicina) – Universidade Federal de Uberlândia, Uberlândia, 2025.
URI:	https://repositorio.ufu.br/handle/123456789/46209
Date of defense:	29-Apr-2025
Appears in Collections:	TCC - Ciências Biomédicas

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.